title: No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
authors.forename: Marianna
authors.initials: M
authors.lastname: Politou
authors.forename: Anastasios
authors.initials: A
authors.lastname: Karadimitris
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Amin
authors.initials: A
authors.lastname: Rahemtulla
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004351:Drug Resistance; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000235:genetics*; D011719:Pyrazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; C088874:PSMB5 protein, human; D046988:Proteasome Endopeptidase Complex